Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Related Posts
Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, Gallo G, Okragly A, Wolf E, Xu C, Moser BA, Rueda MJ, Elmaraghy[...]
Wang Y, Sun B, Ma F, Tao B, Gu Y, Zhou Z, Kim J, Zhang L, Liu Z, Ten Hoeve J, Stiles L, Fernandez-Del-Rio L,[...]
Ma EJ, Roberts AM, Jeong CY, Chou P, Katz A, Nong Y, Johnsen N, Yan M, Ochoa MT, Armstrong AW. GLP-1RAs and cardiovascular risk reduction[...]